CD28 and secretory immunoglobulin A‐dependent activation of eosinophils: inhibition of mediator release by the anti‐allergic drug, suplatast tosilate
Authors:
- 3 September 2004
- journal article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 34 (9) , 1379-1387
Abstract
Summary: Background Eosinophils are major effector cells in allergic diseases. After their recruitment to sites of inflammation, they contribute to the pathophysiology of the disease by releasing granule proteins and cytokines. Suplatast tosilate (IPD‐1151T), a new anti‐allergic agent, has shown beneficial effect in the treatment of asthma, associated with reduced bronchoalveolar lavage eosinophil infiltration and eosinophilic cationic protein (ECP) release in serum and sputum.Objective We investigated whether suplatast tosilate could exert direct effects on human eosinophil activation.Methods Eosinophils from hypereosinophilic patients or normal donors were purified by Percoll gradient and the magnetic cell separation system. Chemotaxis was studied using the Boyden chamber technique using three chemoattractants, formyl‐methionine‐leucine‐phenylalanine (fMLP), IL‐5 and eotaxin. Oxidative metabolism was determined by a luminol‐dependent chemiluminescence assay after activation with eotaxin or secretory IgA (sIgA). The release of ECP and eosinophil derived neurotoxin (EDN) was measured by radioimmunoassay and cytokine production was determined by ELISA following activation with sIgA or anti‐CD28.Results The chemotactic response to fMLP, IL‐5 and eotaxin was significantly inhibited by IPD‐1151T. Suplatast tosilate was partially inhibiting the release of reactive oxygen species (ROS) induced by eotaxin and sIgA. Activation by sIgA and CD28 ligation resulted in the release of ECP and EDN, which was inhibited by IPD‐1151T. Upon activation by anti‐CD28, only IL‐13 production was inhibited by IPD‐1151T, whereas release of IL‐2 and IFN‐γ was not affected. IL‐10 release induced by sIgA was also inhibited by IPD‐1151T. Additionally, the pro‐inflammatory cytokine IL‐6, which was secreted following anti‐CD28 and sIgA stimulation, was strongly inhibited by IPD‐1151T.Conclusion Through inhibition of chemotaxis, IPD‐1151T might limit the number of eosinophils at the inflammation site. Furthermore, it could reduce the pathological potential of eosinophils by inhibiting the release of ROS and cationic proteins, main inflammatory mediators produced by eosinophils. Moreover, the inhibition of immunoregulatory cytokines released by eosinophils could locally modify the immune response.Keywords
This publication has 40 references indexed in Scilit:
- Eosinophil Cytokines2000
- Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilateAnnals of Allergy, Asthma & Immunology, 1999
- IPD-1151T (Suplatast Tosilate) Inhibits Interleukin (IL)-13 Release but Not IL-4 Release From BasophilsThe Japanese Journal of Pharmacology, 1999
- Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue EosinophiliaJournal of Experimental Medicine, 1997
- Eosinophils in allergic reactionsCurrent Opinion in Immunology, 1996
- Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agentsLife Sciences, 1995
- Suppressive effects of IPD-1151T (suplatast-tosilate) on induction of mast cells from normal mouse splenocytesEuropean Journal of Pharmacology, 1994
- Suppression of IgE Production by IPD-1151T (Suplatast Tosilate), a New Dimethylsulfonium Agent: (2) Regulation of Human IgE ResponseThe Japanese Journal of Pharmacology, 1993
- Stimulation of CRP secretion in HepG2 cells: Cooperative effect of dexamethasone and interleukin 6Inflammation Research, 1991
- Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activationJournal of Allergy and Clinical Immunology, 1991